Myasthenia Gravis (MG)

When nerve impulse transmission is interrupted at the neuromuscular junction where nerve cells and muscles connect, due to acetylcholine receptors being blocked or destroyed by antibodies. Acetylcholine receptors activate muscle contractions; thus, their destruction prevents those contractions from occurring.

Weakness of the extrinsic ocular muscles and include drooping of the eyelids, blurred or double vision, difficulty swallowing, shortness of breath, impaired speech, and weakness in the arms, hands, fingers, legs, and neck. MG can also lead to respiratory failure.

Thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, neuromyelitis optica spectrum disorder, and myocarditis.

MG can occur at any age and can impact both males and females. Early-onset MG is diagnosed before age 50, and occurs more commonly in females, whereas late-onset MG (over 50 years) arises mainly in males.

• Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial (2021)
• The epidemiology of myasthenia gravis (2021)
• International consensus guidance for management of myasthenia gravis (2020)
• COVID-19 associated risks and effects in myasthenia gravis (CARE-MG) (2020)

Evidence-Based Management of Generalized Myasthenia Gravis: Current Practices and Emerging Treatment Paradigms

Tune in as renowned experts discuss the underlying pathophysiology and diverse clinical manifestations of gMG, best diagnostic practices, the latest evidence on current and emerging treatments, and collaborative strategies to address the long-term, multisystemic impact of gMG.

This activity is delivered by PRIME Education.